58 research outputs found
The Intermediate Higgs
Two paradigms for the origin of electroweak superconductivity are a weakly
coupled scalar condensate, and a strongly coupled fermion condensate. The
former suffers from a finetuning problem unless there are cancelations to
radiative corrections, while the latter presents potential discrepancies with
precision electroweak physics. Here we present a framework for electroweak
symmetry breaking which interpolates between these two paradigms, and mitigates
their faults. As in Little Higgs theories, the Higgs is a pseudo-Nambu
Goldstone boson, potentially composite. The cutoff sensitivity of the one loop
top quark contribution to the effective potential is canceled by contributions
from additional vector-like quarks, and the cutoff can naturally be higher than
in the minimal Standard Model. Unlike the Little Higgs models, the cutoff
sensitivity from one loop gauge contributions is not canceled. However, such
gauge contributions are naturally small as long as the cutoff is below 6 TeV.
Precision electroweak corrections are suppressed relative to those of
Technicolor or generic Little Higgs theories. In some versions of the
intermediate scenario, the Higgs mass is computable in terms of the masses of
these additional fermions and the Nambu-Goldstone Boson decay constant. In
addition to the Higgs, new scalar and pseudoscalar particles are typically
present at the weak scale
Testing microscopically derived descriptions of nuclear collectivity : Coulomb excitation of 22Mg
Many-body nuclear theory utilizing microscopic or chiral potentials has developed to the point that collectivity might be studied within a microscopic or ab initio framework without the use of effective charges; for example with the proper evolution of the E2 operator, or alternatively, through the use of an appropriate and manageable subset of particle–hole excitations. We present a precise determination of E2 strength in 22Mg and its mirror 22Ne by Coulomb excitation, allowing for rigorous comparisons with theory. No-core symplectic shell-model calculations were performed and agree with the new B(E2) values while in-medium similarity-renormalization-group calculations consistently underpredict the absolute strength, with the missing strength found to have both isoscalar and isovector components. The discrepancy between two microscopic models demonstrates the sensitivity of E2 strength to the choice of many-body approximation employed
Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score
Background: Recent findings strongly support hematopoietic stem cell transplantation (HSCT) in patients with severe presentation of LPS-responsive beige-like anchor protein (LRBA) deficiency, but long-term follow-up and survival data beyond previous patient reports or meta-reviews are scarce for those patients who do not receive a transplant.Objective: This international retrospective study was conducted to elucidate the longitudinal clinical course of patients with LRBA deficiency who do and do not receive a transplant.Method: We assessed disease burden and treatment responses with a specially developed immune deficiency and dysregulation activity score, reflecting the sum and severity of organ involvement and infections, days of hospitalization, supportive care requirements, and performance indices.Results: Of 76 patients with LRBA deficiency from 29 centers (median follow-up, 10 years; range, 1-52), 24 underwent HSCT from 2005 to 2019. The overall survival rate after HSCT (median follow-up, 20 months) was 70.8% (17 of 24 patients); all deaths were due to nonspecific, early, transplant-related mortality. Currently, 82.7% of patients who did not receive a transplant (43 of 52; age range, 3-69 years) are alive. Of 17 HSCT survivors, 7 are in complete remission and 5 are in good partial remission without treatment (together, 12 of 17 [70.6%]). In contrast, only 5 of 43 patients who did not receive a transplant (11.6%) are without immunosuppression. Immune deficiency and dysregulation activity scores were significantly lower in patients who survived HSCT than in those receiving conventional treatment (P = .005) or in patients who received abatacept or sirolimus as compared with other therapies, and in patients with residual LRBA expression. Higher disease burden, longer duration before HSCT, and lung involvement were associated with poor outcome.Conclusion: The lifelong disease activity, implying a need for immunosuppression and risk of malignancy, must be weighed against the risks of HSCT.Transplantation and immunomodulatio
Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review
Structural and functional characterisation of Rhodobacter capsulatus bacterioferritin
SIGLEAvailable from British Library Document Supply Centre-DSC:DXN031365 / BLDSC - British Library Document Supply CentreGBUnited Kingdo
Left ventricular non-compaction in pregnancy
Left-ventricular non-compaction (LVNC) represents an arrest in the normal process of myocardial compaction, resulting in multiple, prominent, persistant trabeculations and deep inter-trabecular recesses communicating with the ventricular cavity. LVNC is a rarely encountered cardiomyopathy and few cases have been reported in pregnancy. In this case report we present a patient who referred to our clinic with symptoms of heart failure during pregnancy and whose echocardiographic examination revealed prominent trabeculations in the left ventricle
Performance of SARC-F Turkish in regard to sarcopenia definitions, muscle mass and functional measures
Role of Chlamydia trachomatis infections in infertility due to tubal factor
PubMedID: 1506064[No abstract available
- …